Zevra Therapeutics, Inc. (ZVRA)

Market Cap	200.90M
Revenue (ttm)	28.01M
Net Income (ttm)	-50.90M
Shares Out	41.85M
EPS (ttm)	-1.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,553
Open	4.940
Previous Close	4.890
Day's Range	4.760 - 5.000
52-Week Range	3.890 - 7.280
Beta	1.87
Analysts	Strong Buy
Price Target	20.00 (+316.67%)
Earnings Date	May 8, 2024

About ZVRA

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2015
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: ZVRA

Financial Performance

In 2023, ZVRA's revenue was $27.46 million, an increase of 170.26% compared to the previous year's $10.16 million. Losses were -$46.05 million, 72.0% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 316.67% from the latest price.

Price Target

$20.0

(316.67% upside)

Analyst Consensus: Strong Buy